News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
264,430 Results
Type
Article (13719)
Company Profile (101)
Press Release (250610)
Section
Business (88039)
Career Advice (465)
Deals (15350)
Drug Delivery (66)
Drug Development (36605)
Employer Resources (49)
FDA (6286)
Job Trends (6193)
News (150222)
Policy (14031)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Pharm Country Standard (1)
Academia (438)
Adcomms (6)
Allergies (28)
Alliances (23208)
ALS (32)
Alzheimer's disease (377)
Antibody-drug conjugate (ADC) (33)
Approvals (6309)
Artificial intelligence (94)
Autoimmune disease (4)
Automation (3)
Bankruptcy (146)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (49)
Biotechnology (40)
Bladder cancer (17)
Brain cancer (14)
Breast cancer (70)
Cancer (525)
Cardiovascular disease (55)
Career advice (406)
Career pathing (10)
CAR-T (17)
Cell therapy (74)
Cervical cancer (4)
Clinical research (30794)
Collaboration (290)
Compensation (119)
Complete response letters (16)
COVID-19 (754)
CRISPR (18)
C-suite (100)
Cystic fibrosis (35)
Data (527)
Denatured (15)
Depression (9)
Diabetes (70)
Diagnostics (1311)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (51)
Drug pricing (62)
Drug shortages (12)
Duchenne muscular dystrophy (26)
Earnings (31898)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37289)
Executive appointments (325)
FDA (6624)
Featured Employer (21)
Friedreich's ataxia (2)
Funding (182)
Gene editing (34)
Generative AI (8)
Gene therapy (90)
GLP-1 (325)
Government (1282)
Grass and pollen (2)
Guidances (15)
Healthcare (3557)
Huntington's disease (4)
IgA nephropathy (8)
Immunology and inflammation (26)
Indications (10)
Infectious disease (784)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (35)
Interviews (59)
IPO (5878)
IRA (29)
Job creations (2050)
Job search strategy (372)
Kidney cancer (6)
Labor market (7)
Layoffs (175)
Leadership (3)
Legal (3428)
Liver cancer (18)
Lung cancer (72)
Lymphoma (45)
Machine learning (1)
Management (16)
Manufacturing (128)
MASH (28)
Medical device (1272)
Medtech (1274)
Mergers & acquisitions (9625)
Metabolic disorders (223)
Multiple sclerosis (16)
NASH (14)
Neurodegenerative disease (19)
Neuropsychiatric disorders (5)
Neuroscience (529)
NextGen: Class of 2025 (1585)
Non-profit (593)
Northern California (622)
Now hiring (7)
Obesity (127)
Opinion (116)
Ovarian cancer (18)
Pain (45)
Pancreatic cancer (13)
Parkinson's disease (39)
Partnered (5)
Patents (92)
Patient recruitment (26)
Peanut (9)
People (28785)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8013)
Phase II (13024)
Phase III (11692)
Pipeline (307)
Podcasts (44)
Policy (56)
Postmarket research (1401)
Preclinical (3194)
Press Release (25)
Prostate cancer (40)
Psychedelics (8)
Radiopharmaceuticals (118)
Rare diseases (148)
Real estate (2633)
Recruiting (17)
Regulatory (10031)
Reports (13)
Research institute (563)
Resumes & cover letters (55)
RSV (6)
Schizophrenia (31)
Series A (32)
Series B (11)
Service/supplier (3)
Sickle cell disease (30)
Southern California (624)
Special edition (5)
Sponsored (6)
Startups (1626)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (28)
United States (6268)
Vaccines (137)
Venture capitalists (13)
Webinars (10)
Weight loss (90)
Women's health (8)
Worklife (3)
Date
Today (60)
Last 7 days (266)
Last 30 days (1118)
Last 365 days (12373)
2025 (2172)
2024 (12513)
2023 (14258)
2022 (19562)
2021 (20087)
2020 (19066)
2019 (14897)
2018 (11723)
2017 (13897)
2016 (13131)
2015 (15474)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (47)
Arkansas (3)
Asia (20021)
Australia (2596)
California (1499)
Canada (814)
China (195)
Colorado (61)
Connecticut (62)
Delaware (49)
Europe (39229)
Florida (267)
Georgia (34)
Idaho (9)
Illinois (167)
India (11)
Indiana (121)
Iowa (1)
Japan (76)
Kansas (54)
Kentucky (12)
Maine (2)
Maryland (231)
Massachusetts (1285)
Michigan (27)
Minnesota (83)
Missouri (22)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (649)
New Mexico (7)
New York (427)
North Carolina (357)
North Dakota (2)
Northern California (622)
Ohio (43)
Oklahoma (4)
Oregon (16)
Pennsylvania (377)
Puerto Rico (5)
Rhode Island (5)
South America (500)
South Carolina (2)
Southern California (624)
Tennessee (29)
Texas (198)
Utah (32)
Virginia (65)
Washington D.C. (29)
Washington State (101)
Wisconsin (12)
264,430 Results for "beyondspring pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today provided a business update and reported results for the year ended December 31, 2023.
April 29, 2024
·
10 min read
Press Releases
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
January 28, 2025
·
10 min read
Business
BeyondSpring Files 2023 Annual Report on Form 20-F
BeyondSpring Inc. announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission on April 29, 2024.
April 29, 2024
·
2 min read
Pharm Country
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”) today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET.
May 3, 2024
·
5 min read
Pharm Country
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
BeyondSpring Inc. announced that it hosted a virtual Research and Development Day to discuss its lead asset Plinabulin, a dendritic cell maturation agent, in drug combinations to potentially address the current unmet medical needs in cancer indications where patients failed prior PD-1/PD-L1 inhibitors, as well as updates for SEED Therapeutics which focuses on target protein degradation platform for innovative molecular glue drug discovery on May 15, 2024.
May 16, 2024
·
9 min read
Pharm Country
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
BeyondSpring Inc. announced that on February 20, 2024, the Company received a written notification on minimum bid price compliance from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.
February 26, 2024
·
1 min read
Policy
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
BeyondSpring Inc. announced that on January 4, 2024, it received a Foreign Delinquency Compliance Plan Alert Letter from The Nasdaq Stock Market LLC.
January 10, 2024
·
1 min read
Drug Development
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
BeyondSpring Inc. today announced that the first patient has been dosed in a Phase 2 investigator-initiated trial (IIT) with Pembrolizumab, Plinabulin.
March 25, 2024
·
4 min read
Pharm Country
BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”) today announced that management will present and participate in the R.W. Baird’s 2023 Global Healthcare Conference, taking place on September 12 to 13, 2023 in New York City.
September 7, 2023
·
1 min read
Pharm Country
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
BeyondSpring Inc. announced that on October 27, 2023, it received a written notification from the Listing Qualifications Department from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550 of the Nasdaq Listing Rules.
October 30, 2023
·
1 min read
1 of 26,443
Next
